BEIGENE LTD 20 MAY 2025_EN
Guardado en:
| Publicado en: | Company SnapShot (May 20, 2025), p. n/a |
|---|---|
| Publicado: |
Acquisdata Pty Ltd
|
| Materias: | |
| Acceso en línea: | Citation Full Text Full Text - PDF |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
MARC
| LEADER | 00000nab a2200000uu 4500 | ||
|---|---|---|---|
| 001 | 3206805249 | ||
| 003 | UK-CbPIL | ||
| 022 | |a 2203-2746 | ||
| 035 | |a 3206805249 | ||
| 045 | 0 | |b d20250520 | |
| 084 | |a 239636 |2 nlm | ||
| 245 | 1 | |a BEIGENE LTD 20 MAY 2025_EN | |
| 260 | |b Acquisdata Pty Ltd |c May 20, 2025 | ||
| 513 | |a Company Profile | ||
| 610 | 4 | |a BeiGene Ltd | |
| 651 | 4 | |a Europe | |
| 651 | 4 | |a Switzerland | |
| 651 | 4 | |a United States--US | |
| 651 | 4 | |a China | |
| 651 | 4 | |a Japan | |
| 653 | |a Enrollments | ||
| 653 | |a GAAP | ||
| 653 | |a Metastasis | ||
| 653 | |a Cancer therapies | ||
| 653 | |a Earnings per share | ||
| 653 | |a Esophageal cancer | ||
| 653 | |a Leadership | ||
| 653 | |a Oncology | ||
| 653 | |a Research & development--R&D | ||
| 653 | |a Corporate profits | ||
| 653 | |a Hematology | ||
| 653 | |a Market shares | ||
| 653 | |a Drug dosages | ||
| 653 | |a Lung cancer | ||
| 653 | |a FDA approval | ||
| 653 | |a Operating leverage | ||
| 653 | |a Financial performance | ||
| 653 | |a Chemotherapy | ||
| 653 | |a Profitability | ||
| 773 | 0 | |t Company SnapShot |g (May 20, 2025), p. n/a | |
| 786 | 0 | |d ProQuest |t ABI/INFORM Trade & Industry | |
| 856 | 4 | 1 | |3 Citation |u https://www.proquest.com/docview/3206805249/citation/embedded/75I98GEZK8WCJMPQ?source=fedsrch |
| 856 | 4 | 0 | |3 Full Text |u https://www.proquest.com/docview/3206805249/fulltext/embedded/75I98GEZK8WCJMPQ?source=fedsrch |
| 856 | 4 | 0 | |3 Full Text - PDF |u https://www.proquest.com/docview/3206805249/fulltextPDF/embedded/75I98GEZK8WCJMPQ?source=fedsrch |